|
|
Nicox SA - Comparative Business Analysis Snapshot
Business Description
Nicox SA. The Group's principal activity is to develop nitric-oxide donating drugs targeting the therapeutic area. The Group offers biopharmaceutical therapeutics to treat ailments such as osteoarthritis, diabetes, inflammation and cardio metabolic diseases. The Group markets its products under the brand names Naproxcinod, NCX 4016 and NCX 6560. The Group also works in association with major pharmaceutical companies such as Pfizer, Merck and Group Ferrer. The Group operates in France.
Competitor Analysis
This analysis compares Nicox SA with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
